Kinase inhibitors

Abstract

The present invention provides kinase inhibitors of Formula I.

1 - 10 . (canceled) 
   
   
       11 . A method of treating breast cancer comprising administering to a mammal in need of such treatment an effective amount of a compound of the formula: 
     
       
         
         
             
             
         
       
     
     where:
 W is: 
 
     
       
         
         
             
             
         
       
       X is N, or C-R 1 ; 
       R is C 1 -C 7  alkyl, C 3 -C 7  cycloalkyl, (C 1 -C 7  alkylene)-(C 3 -C 7  cycloalkyl), —SO 2 —(C 1 -C 7  alkyl), or —SO 2 —NR 5 R 6 ; 
       R 1  is hydrogen, amino, methyl, or —N=CH(NMe) 2 ; 
       R 2  is phenyl optionally substituted with one or two substituents independently selected from halo; 
       R 3  is hydrogen, C 1 -C 7  alkyl, C 3 -C 7  cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl; 
       R 4  is hydrogen or C 1 -C 7  alkyl; 
       R 5  and R 6  are independently selected from the group consisting of C 1 -C 7  alkyl; or a pharmaceutically acceptable salt thereof. 
     
   
   
       12 . A method of treating breast cancer comprising administering to a mammal in need of such treatment an effective amount of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate. 
   
   
       13 . A method of treating prostate cancer comprising administering to a mammal in need of such treatment an effective amount of a compound of the formula: 
     
       
         
         
             
             
         
       
     
     where:
 W is: 
 
     
       
         
         
             
             
         
       
       X is N, or C-R 1 ; 
       R is C 1 -C 7  alkyl, C 3 -C 7  cycloalkyl, (C 1 -C 7  alkylene)-(C 3 -C 7  cycloalkyl), —SO 2 —(C 1 -C 7  alkyl), or —SO 2 —NR 5 R 6 ; 
       R 1  is hydrogen, amino, methyl, or —N=CH(NMe) 2 ; 
       R 2  is phenyl optionally substituted with one or two substituents independently selected from halo; 
       R 3  is hydrogen, C 1 -C 7  alkyl, C 3 -C 7  cycloalkyl, or phenyl optionally substituted with one or two substituents independently selected from halo and trifluoromethyl; 
       R 4  is hydrogen or C 1 -C 7  alkyl; 
       R 5  and R 6  are independently selected from the group consisting of C 1 -C 7  alkyl; or a pharmaceutically acceptable salt thereof. 
     
   
   
       14 . A method of treating prostate cancer comprising administering to a mammal in need of such treatment an effective amount of 5-[2-tert-butyl-5-(4-fluoro-phenyl)-1H-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3H-imidazo[4,5-b]pyridin-2-ylamine dimethanesulfonate.